Flexion Therapeutics Inc (FLXN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

10 MALL ROAD BURLINGTON, MA 01803

Flexion Therapeutics Inc discovers and develops therapeutics for musculoskeletal disorders. The company offers pharmaceuticals and developed delivery systems for the treatment of refractory end-stage pain.

Data as of 2020-10-17
Market Cap661.645 Million Shares Outstanding49.303 Million Avg 30-day Volume608.76 Thousand
P/E Ratio Dividend Yield EPS-3.58
Price/Sales11.17 Price cash flow ratio Price free cash flow ratio-6.9
Book Value0.34 Price to Tangible Book40.09 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.175796
BETA1.91249 52-week High/Low22.98 / 5.01 Stddev0.195894
View SEC Filings from FLXN instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 1 100.0% 3 (0.2%) 1 (0.06%) 200.0%
Funds Holding: 125 124 0.81% 36 (2.35%) 40 (2.56%) -10.0%
13F shares: 44.976 Million 31.853 Million 41.2% 16.473 Million 10.58 Million 55.7%
% Ownership 91.2331 82.625 10.42% 33.4157 27.4441 21.76%
New Positions: 25 21 19.05% 10 10 0.0%
Increased Positions 53 39 35.9% 20 13 53.85%
Closed Positions 22 29 -24.14% 14 13 7.69%
Reduced Positions 22 36 -38.89% 3 11 -72.73%
Total Calls 250.979 Thousand 284.691 Thousand -11.84% 74.7 Thousand 30.1 Thousand 148.17%
Total Puts 293.11 Thousand 97.777 Thousand 199.77% 225.5 Thousand 41.6 Thousand 442.07%
PUT/CALL Ratio 1.17 0.34 244.12% 3.02 1.38 118.84%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding FLXN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FLXN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KWO ELIZABETH

  • Director
0 2020-08-18 2

CLAYMAN MICHAEL D. PRESIDENT AND CEO

  • Officer
  • Director
919,898 2020-07-16 5

LEVINE MARK S. GENERAL COUNSEL

  • Officer
114,260 2020-07-16 4

KELLEY SCOTT CHIEF MEDICAL OFFICER

  • Officer
119,710 2020-07-16 4

WENTWORTH KERRY CHIEF REGULATORY OFFICER

  • Officer
126,180 2020-07-16 4

ARKOWITZ DAVID CHIEF FINANCIAL OFFICER

  • Officer
157,121 2020-07-16 5

WILLWERTH CHRISTINA CHIEF STRATEGY OFFICER

  • Officer
121,788 2020-07-16 4

MILINAZZO ALAN

  • Director
22,950 2020-07-09 2

MAHATME SANDESH

  • Director
4,500 2020-06-10 1

CANUTE SCOTT A

  • Director
4,500 2020-06-10 1

MAHAFFY PATRICK J

  • Director
35,324 2020-06-10 1

COLELLA SAMUEL D

  • Director
  • 10% Owner
4,001,429 2020-06-10 1

LUKATCH HEATH

  • Director
4,500 2020-06-10 1

MERRIFIELD C ANN

  • Director
14,500 2020-06-10 1

STEJBACH MARK

  • Director
8,131 2020-06-10 2

LAYMAN MELISSA CHIEF COMMERCIAL OFFICER

  • Officer
61,000 2020-04-01 2

BODICK NEIL CHIEF SCIENTIFIC OFFICER

  • Officer
489,836 2020-01-03 1

DENIZ YAMO CHIEF MEDICAL OFFICER

  • Officer
9,000 2017-08-28 0

DRISCOLL FREDERICK W CHIEF FINANCIAL OFFICER

  • Officer
7,777 2017-03-23 0

VERSANT VENTURES III, LLC

VERSANT VENTURE CAPITAL III, L.P.

VERSANT SIDE FUND III, L.P.

VERSANT DEVELOPMENT FUND III, L.P.

ATWOOD BRIAN G

COLELLA SAMUEL D

JAFFE ROSS A MD

LINK WILLIAM J PHD

MILDER DONALD B

ROBERTSON REBECCA B

  • 10% Owner
3,921,092 2016-06-08 0

LUBASH BARBARA N

BOLZON BRADLEY J PHD

WARDEN CHARLES M

PRAEGER ROBIN L.

  • 10% Owner
3,921,092 2016-06-08 0

NOVO A/S

  • 10% Owner
No longer subject to file 2015-06-18 0

SOFINNOVA PARTNERS SAS

  • 10% Owner
No longer subject to file 2014-10-29 0

VERSANT VENTURE CAPITAL III, L.P.

VERSANT VENTURES III, LLC

VERSANT SIDE FUND III, L.P.

ATWOOD BRIAN G

COLELLA SAMUEL D

JAFFE ROSS A MD

LINK WILLIAM J PHD

MILDER DONALD B

LUBASH BARBARA N

ROBERTSON REBECCA B

  • Director
  • 10% Owner
2,250 2014-09-10 0

VERSANT VENTURE CAPITAL III, L.P.

BOLZON BRADLEY J PHD

WARDEN CHARLES M

VERSANT DEVELOPMENT FUND III, L.P.

  • Director
  • 10% Owner
2,250 2014-09-10 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments